Grey Wolf Therapeutics
Grey Wolf Therapeutics

Grey Wolf Therapeutics

Novel antigen modulation technology to guide the immune system

Grey Wolf Therapeutics is developing next-generation immunotherapies that restore the body’s ‘immune signals’, revealing diseases to the body’s defences.

The company is conducting clinical trials in oncology and autoimmune disorders and has an earlier stage virology program.

Sector
Life Sciences
Stage
  • Series B+
OSE Manager Limited, a wholly owned subsidiary of Oxford Science Enterprises plc, is authorised and regulated by the Financial Conduct Authority.